Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 69Carcinoma, Intraductal, Noninfiltrating 9Breast Carcinoma In Situ 6Breast Neoplasms, Male 5Neoplasms 3Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Inflammatory Breast Neoplasms 2Sleep Wake Disorders 1Risk Reduction Behavior 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Obesity 1Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer 1Mastodynia 1Glioma 1Fibrocystic Breast Disease 1Fibroadenoma 1Fatigue 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Disease Progression 1Desmoid Tumors 1Cystic Fibrosis 1Cystadenocarcinoma, Serous 1Carcinoma, Ovarian Epithelial 1Carcinoma, Lobular 1Bulbo-Spinal Atrophy, X-Linked 1Breast Cancer Metastatic 1

Interventions

Tamoxifen 1Medroxyprogesterone Acetate 1Letrozole 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced, Persistent, or Recurrent Endometrial Cancer × Tamoxifen × Clear all
NCT02228681 2024-09-19

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

GOG Foundation

Phase 2 Completed
74 enrolled 13 charts
Gynecologic

Advanced, Persistent, or Recurrent Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡